Edgar Almeida

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Autosomal dominant polycystic kidney disease: evidence for the existence of a third locus in a Portuguese family

Salomé de Almeida, Edgar Almeida, Dorien J.M. Peters et al. · Human Genetics · 1995 · 113 citations

Mendelian Disorder, Portuguese Family, Medicine +11

Dental Health and Mortality in People With End-Stage Kidney Disease Treated With Hemodialysis: A Multinational Cohort Study

Suetonia C. Palmer, Marinella Ruospo, Germaine Wong et al. · American Journal of Kidney Diseases · 2015 · 82 citations · Full text

Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families

Binu M. Paul, Mark Consugar, Moonnoh Ryan Lee et al. · Kidney International · 2013 · 45 citations · Full text

Genetic Disorder, Genetics, Designated Pkd3 Families +5